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Other names: CCN2; Fisp12; betaIG-M2; Hcs24; 
HBGF-0.8; ecogenin; IGFBP8; IGFBP-rP3 
Location: 6q23.1 
Note: CCN family protein 2/connective tissue growth 
factor (CCN2/CTGF) was initially identified in the 
culture supernatant of vascular endothelial cells. 
Subsequently, the CCN2/CTGF gene has been 
classified as a representative member of the CCN gene 
family that is an acronym of the original names of the 3 
early members, Cyr61, CTGF and NOV. 
The mammalian genome contains 6 functional CCN 
family members, which were renamed based on the 
proposal of a unified nomenclature. 
CCN2/CTGF displays multiple functions via 
interaction with a variety of other molecules. It is
important to note that CCN2/CTGF induces the 
development and regeneration of mesenchymal tissues 




Unlike the other CCN family members, the 
CCN2/CTGF gene is conserved among all of the 
vertebrates and several invertebrates. 
In Drosophila melanogaster, only one gene is 
designated as ccn, which is thought to have evolved 
from a prototypic CCN2/CTGF gene. Therefore, 
CCN2/CTGF may be regarded evolutionarily as an 
oldest gene in the CCN family. Consistent with such 
findings, human CCN2/CTGF gene is also quite 
compact. The total transcribed sequence is as shortas 
3.2 kb, and contains 4 intronic sequences of less than
400 bp. 
Transcription 
The mature mRNA, 2.3 kb in length, is formed by 
connecting 5 exons encoding a signal peptide, an 
IGFBP module, a VWC module, a TSP1 module and 
CT module in the order. The last exon yields a long 3'-
untranslated region of more than1.0 kb on the mRNA, 
which contains the critical elements for post-
transcriptional regulation. The proximal promoter area 
upstream of the transcription initiation site is known to 





Structure of human CCN2/CTGF and its mRNA. Abbreviations S, I, V, T, and C denote the coding regions for the signal peptide, IGFBP 
module, VWC module, TSP1 module and CT module, respectively. 
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Protein 
Description 
The CCN2/CTGF is composed of 4 distinct modules:  
the N-terminal signal peptide for secretion; insulin-like 
growth factor binding protein-like (IGFBP) module, 
von Willebrand factor type-C repeat (VWC) module, 
thrombospondin type 1 repeat (TSP1) module and the 
C-terminal cystine knot (CT) module. 
This is consistent with other CCN family proteins. 
Because of this unique structure, the 6 CCN2/CTGF-
related proteins are thought to form a distinct protein 
class which is distinct from the IGFBP family, despite 
the involvement of IGFBP module. The involvement of 
cysteine residues that are also conserved among the 
CCN family members is a prominent structural 
characteristic. All of the 4 modules are highly 
interactive with other biomolecules including growth 
factors, cell-surface receptor molecules and 
extracellular matrix components. In addition, the 
tetramodular construction of these modules provides 
the structural basis for the multiple functionality of 




Interaction of each module in CCN2/CTGF with other growth 
factors. 
Expression 
CCN2/CTGF is differentially expressed in certain 
tissues and organs, particularly in the cardiovascul r, 
gonadal, renal and skeletal systems, during 
development of vertebrates. The cell population that 
expresses the CCN2/CTGF gene is highly restricted in 
each tissue; for example, this factor is produced in 
cartilage primarily by pre-hypertrophic and 
hypertrophic chondrocytes, in fact, it was previously 
referred to as hypertrophic chondrocyte-specific protein 
24 (Hcs24). 
Localisation 
In addition to the tissues containing the cells which 
express this protein described above, CCN2/CTGF is 
abundantly present in platelets, although its origin is 
still unknown.  
Function 
Under the multiple interactions with specific molecular 
counterparts, CCN2/CTGF conducts the local 
information network of extracellular signaling 
molecules and exerts multiple functions, depending 
upon the microenvironmental conditions. Indeed, 
CCN2/CTGF promotes both proliferation and 
differentiation of mesenchymal stem cells, 
chondrocytes, osteoblasts, periodontal ligament cells, 
fibroblasts and vascular endothelial cells in vitro. As a 
result of these effects, this factor enhances wound 
healing and tissue regeneration of cartilage and bone. 
Homology 
CCN2/CTGF is structurally homologous to the other 5 
CCN family members. The cysteine residues are highly 
conserved among the members. 
Mutations 
Germinal 
Until today, no association between mutations in the
CCN2/CTGF gene and specific genetic diseases has 
been described. In mouse models, deletion of both 
CCN2/CTGF alleles results in severe skeletal 
malformation, leading to respiratory failure upon 
delivery. Histological and cell biological analysis 
revealed that the endochondral ossification process was 
specifically affected by the CCN2/CTGF deletion, 
particularly at the final stage that is supported by blood 
vessel invasion. However, no apparent phenotypic 
complication has been observed in CCN2/CTGF (-/+) 
heterozygous mice. 
Somatic 
At present, nearly 30 SNPs have been described in the 
NCBI database. Among the SNPs, 35.7% and 39.3% of 
the total cases have been reported to exist outside of the 
transcribed area and in the areas of untranslated regions 
(UTRs) and introns, respectively. Mutation/variation in 
the open reading frame (ORF) was found in 25% of the 
total. Missense mutation occurred at a frequency of 
42.7 %, whereas the other cases were silent. Excluding 
the UTRs, the IGFBP-encoding 2nd exon has been a 
hot spot of mutation and variation (57.1% of the one 
within ORF). In a single case, an African population 
was analyzed to compute the actual frequency. This 
demonstrated that the frequency of a mutation in the 
3rd exon, which caused a missense change of amino 
acid 118 from asparagine to serine by an A to G 
transition, was 1.3%. Including these cases, no 
association of a SNP in the CCN2/CTGF gene with any 















Although the CCN2/CTGF expression is observed in a 
number of different types of malignant neoplasm, the
role of CCN2/CTGF in oncogenesis and its association 
with malignant phenotypes are quite controversial. 
According to a previous study, a positive correlation 
was observed between the level of CCN2/CTGF 
expression and the degree of malignancy in breast 
cancer and colorectal cancer cases. These findings are 
consistent with other recent reports describing the
contribution of CCN/CTGF in developing bone 
metastasis of breast cancers. The ability to promote 
metastasis can be partially ascribed to the angiogen c 
activity of CCN2/CTGF. 
However, over expression of CCN2/CTGF in cells of 
the same origin is reported to induce apoptosis. 
Furthermore, in chondrosarcoma cases, patients with 
higher CCN2/CTGF expression in tumors survived 
longer than those with lower CCN2/CTGF expression. 
These findings are consistent with the observation that 
overexpression of CCN2/CTGF results in benign 
conversion of the phenotype in oral squamous 
carcinoma cells and induces cell cycle arrest in 
fibroblasts. The observations above suggest that 
CCN2/CTGF produced by tumor cells may exert 
paracrine angiogenic and autocrine/intracrine anti-
proliferative effects in solid tumors. 
Fibrotic disorders 
Disease 
Since its initial discovery, CCN2/CTGF has been 
widely known as a profibrotic factor that is involved in 
a variety of fibrotic disorders. 
CCN2/CTGF is associated with systemic sclerosis, 
keloids, pulmonary fibrosis, diabetic renal fibrosis, 
liver cirrhosis, pancreatic fibrosis, atherosclerosis, 
myocardial fibrosis, biliary atresia and cataracts. 
Since CCN2/CTGF has a positive role in wound 
healing and mesenchymal tissue regeneration, the 
fibrotic changes observed in those diseases may be 
regarded as a result of dysregulated regeneration of 
corresponding tissues. 
Prognosis 
Fibrotic changes are usually irreversible; however, 
antibody-mediated molecular therapeutics against 
CCN2/CTGF is currently being developed to prevent 
the development of fibrotic lesions. 
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